| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
585,690,000 |
| Market
Cap: |
186.89(B) |
| Last
Volume: |
2,555,459 |
Avg
Vol: |
2,663,996 |
| 52
Week Range: |
$255.7 - $335.97 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 100 |
|
S&P 500 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 442 |
| Guru Rank Value : 4.5 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
2,117 |
14,213 |
24,703 |
| Total Sell Value |
$0 |
$662,802 |
$3,963,214 |
$6,744,849 |
| Total People Sold |
0 |
1 |
2 |
4 |
| Total Sell Transactions |
0 |
1 |
3 |
6 |
| End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hooper Anthony C |
EVP, Global Commercial Ops. |
• • – |
2016-03-25 |
4 |
D |
$149.24 |
$3,549,673 |
D/D |
(23,785) |
185,855 |
|
- |
|
| Tross Stuart A |
SVP, Human Resources |
• • – |
2016-03-25 |
4 |
D |
$149.24 |
$403,396 |
D/D |
(2,703) |
24,060 |
|
- |
|
| Such Annette Louise |
VP, Finance and CAO |
• • – |
2016-03-25 |
4 |
D |
$149.24 |
$108,796 |
D/D |
(729) |
9,919 |
|
- |
|
| Piacquad David |
SVP, Business Development |
• • – |
2016-03-25 |
4 |
D |
$149.24 |
$344,297 |
D/D |
(2,307) |
31,999 |
|
- |
|
| Patton Cynthia M |
SVP & CCO |
• • – |
2016-03-25 |
4 |
D |
$149.24 |
$948,271 |
D/D |
(6,354) |
21,108 |
|
- |
|
| Mcnamee Brian M |
EVP |
• • – |
2016-03-25 |
4 |
D |
$149.24 |
$2,091,748 |
D/D |
(14,016) |
89,226 |
|
- |
|
| Harper Sean E |
EVP, Research & Development |
• • – |
2016-03-25 |
4 |
D |
$149.24 |
$3,549,673 |
D/D |
(23,785) |
65,782 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2016-03-25 |
4 |
D |
$149.24 |
$8,874,407 |
D/D |
(59,464) |
344,887 |
|
- |
|
| Herringer Frank C |
Director |
• • – |
2016-03-14 |
4 |
D |
$144.57 |
$252,275 |
D/D |
(1,745) |
28,863 |
|
- |
|
| Herringer Frank C |
Director |
• • – |
2016-03-14 |
4 |
OE |
$50.44 |
$252,200 |
D/D |
5,000 |
30,608 |
|
- |
|
| Coffman Vance D |
Director |
• • – |
2016-03-09 |
4 |
D |
$144.63 |
$252,235 |
D/D |
(1,744) |
41,703 |
|
- |
|
| Coffman Vance D |
Director |
• • – |
2016-03-09 |
4 |
OE |
$50.44 |
$252,200 |
D/D |
5,000 |
43,447 |
|
- |
|
| Tross Stuart A |
SVP, Human Resources |
• • – |
2016-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
6,200 |
26,678 |
|
- |
|
| Such Annette Louise |
CAO |
• • – |
2016-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,926 |
10,607 |
|
- |
|
| Piacquad David |
SVP, Business Development |
• • – |
2016-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,305 |
34,212 |
|
- |
|
| Mcnamee Brian M |
EVP |
• • – |
2016-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
26,877 |
102,959 |
|
- |
|
| Patton Cynthia M |
SVP & CCO |
• • – |
2016-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,731 |
27,342 |
|
- |
|
| Hooper Anthony C |
EVP, Global Commercial Ops. |
• • – |
2016-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
45,268 |
209,230 |
|
- |
|
| Harper Sean E |
EVP, Research & Development |
• • – |
2016-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
45,268 |
89,162 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2016-03-02 |
4 |
D |
$148.39 |
$6,499,334 |
D/D |
(43,799) |
403,303 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2016-03-02 |
4 |
OE |
$50.44 |
$4,236,960 |
D/D |
84,000 |
447,102 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2016-03-02 |
4 |
S |
$146.48 |
$2,929,566 |
D/D |
(20,000) |
383,102 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2016-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
113,175 |
383,102 |
|
- |
|
| Balachandran Madhavan |
EVP, Operations |
• • – |
2016-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
45,268 |
65,570 |
|
- |
|
| Tross Stuart A |
SVP, Human Resources |
• • – |
2016-01-31 |
4 |
D |
$152.73 |
$38,335 |
D/D |
(251) |
20,478 |
|
- |
|
2210 Records found
|
|
Page 32 of 89 |
|
|
6.24 (1.99%) 
